Novartis hears pitches to consolidate its agency roster

Share this article:
Novartis has heard pitches for its consumer and professional advertising business with a view toward consolidating its agency roster into 2-4 integrated shops.
The company's global advertising head, Kurt Graves, told Advertising Age that Novartis was torn between seeking global bulk and creative brawn in both consumer and professional. "Nobody has both," Graves told Advertising Age, adding that he had ruled out consolidating Novartis' advertising business into one holding company, as Sanofi-Synthelabo did recently with Publicis Groupe.
Included in the pitch were Deutsch, which handles Lamisil and Zelnorm DTC, Merkley & Partners, which handles Elidel DTC, and Commonhealth Group's Noesis, which handles Elidel and Lotrel professional, as well as non-roster shops such as InChord's GSW Worldwide, DDB Worldwide, Saatchi & Saatchi. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...